Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial
Title:
Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial
Author:
Sabatine, Marc S Leiter, Lawrence A Wiviott, Stephen D Giugliano, Robert P Deedwania, Prakash De Ferrari, Gaetano M Murphy, Sabina A Kuder, Julia F Gouni-Berthold, Ioanna Lewis, Basil S Handelsman, Yehuda Pineda, Armando Lira Honarpour, Narimon Keech, Anthony C Sever, Peter S Pedersen, Terje R